News

Data Curation and Entry in DIDB – February Summary

In February, we added 119 citations in DIDB, including 57 in vitro (with 21 articles published in February 2024) and 62 in vivo articles (with 35 articles published in February 2024).

4 NDAs approved in 2023 and 1 NDA approved in 2024, including berdazimer (ZELSUVMI), birch triterpenes (FILSUVEZ), eplontersen (WAIHUA), iptacopan (FABHALTA), zuranolone (ZURZUVAE), were also curated in DIDB.

We are pleased to let you know that all the NDAs and BLAs approved in 2023 (n = 55) have been entered in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – January Summary

In January, we added 117 citations in DIDB, including 54 in vitro (with 21 articles published in January 2024) and 63 in vivo articles (with 39 articles published in January 2024).

6 NDA/BLAs approved in 2023, including capivasertib (TRUQAP), efbemalenograstim (RYZNEUTA), epcoritamab (EPKINLY), mirikizumab (OMVOH), nirogacestat (OGSIVEO), and rezafungin (REZZAYO), were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

DDI Marker Studies Knowledgebase – quarterly update

The DDI Marker Studies Knowledgebase has been updated in January 2024, and is available in the DIDB Resource Center.

In this update, 42 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 3 compounds were sensitive substrates, and 3 compounds were strong inhibitors, which could lead to strong drug interactions mediated by CYP1A2, CYP2C19, and CYP3A.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – December Summary

In December, we added 76 citations in DIDB, including 32 in vitro (with 22 articles published in December 2023) and 44 in vivo articles (with 36 articles published in December 2023).

5 NDA/BLAs approved in 2023, including fruquintinib (FRUZAQLA), gepirone (EXXUA), repotrectinib (AUGTYRO), toripalimab (LOQTORZI), vamorolone (AGAMREE), were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – November Summary

In November, we added 105 citations in DIDB, including 44 in vitro (with 18 articles published in November 2023) and 61 in vivo articles (with 31 articles published in November 2023).

6 NDA/BLAs: bimekizumab (BIMZELX), cipaglucosidase alfa (POMBILITI), etrasimod (VELSIPITY), motixafortide (APHEXDA), nedosiran (RIVFLOZA), zilucoplan (ZILBRYSQ).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

PMRs/PMCs for drugs approved by the FDA in 2014, 2015, and 2016 – Additional information now available in DIDB

As the DIDB content continues to expand, we are pleased to announce that post-marketing requirements and post-marketing commitments (PMRs and PMCs) for drugs approved by the FDA in 2014, 2015, and 2016 have now been entered in the DIDB. The DDI, hepatic impairment, and renal impairment results can be found under the drug’s original NDA or BLA numbers. Updated label recommendations are also presented in the drug DDI Summary.

Having access to this additional information is key to fully understand the DDI profile of NMEs, and the DIDB Editorial Team is now working on PMR/PMC data for drugs approved in 2017 and 2018.

As always, feel free to contact us at DIDBase@certara.com if you have any questions or comments.

Data Curation and Entry in DIDB – October Summary

In October, we added 110 citations in DIDB, including 47 in vitro (with 16 articles published in October 2023) and 63 in vivo articles (with 38 articles published in October 2023).

4 recently approved NDAs/BLAs were also added: elranatamab (ELREXFIO), momelotinib (OJJAARA), pozelimab (VEOPOZ), sotagliflozin (INPEFA).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Video tutorials for DIDB users – Updated

Did you know that we have recently recorded / updated 19 training videos to help DIDB users to make full use of the database?

Those videos are available in the DIDB Resource Center as well as on the DIDB pages that are relevant to their content. For example, on the Drug Query page you have access to 3 related videos, on the QT Interval page to 1 related video …

Please note that you must be signed-in to access.

Feel free to suggest additional topics for training videos that you will find useful. Please contact us. Thank you.

DDI Marker Studies Knowledgebase – quarterly update

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in October 2023, and is available in the DIDB Resource Center.

In this update, 35 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 2 compounds were sensitive substrates and 3 compounds were strong inhibitors which could lead to strong drug interactions mediated by CYP2D6 and CYP3A.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – September Summary

In September, we added 74 citations in DIDB, including 33 in vitro (with 12 articles published in September 2023) and 41 in vivo articles (with 22 articles published in September 2023).

6 recently approved NDAs/BLAs were also added: avacincaptad pegol (IZERVAY), lotilaner (XDEMVY), nirmatrelvir and ritonavir (PAXLOVID),palovarotene (SOHONOS),  somatrogon (NGENLA), talquetamab (TALVEY).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.